Literature DB >> 29198898

Levels of prebeta-1 high-density lipoprotein are elevated in 3 phenotypes of dyslipidemia.

Eveline Oestreicher Stock1, Christine T Ferrara2, Patricia M O'Connor3, Josefina M Naya-Vigne4, Philip H Frost1, Mary J Malloy5, John P Kane6, Clive R Pullinger7.   

Abstract

BACKGROUND: Prebeta-1 high-density lipoprotein (HDL) is a small subspecies of HDL that functions as the HDL quantum particle and is the principal acceptor of cholesterol effluxed from macrophages through the ATP-binding cassette transporter, ABCA1. High levels of prebeta-1 HDL are associated with increased risk of structural coronary artery disease and myocardial infarction.
OBJECTIVE: We aimed to compare prebeta-1 HDL levels in normal subjects and in 3 phenotypes of dyslipidemia.
METHODS: We studied 2435 individuals (1388 women; 1047 men). Of these, 2018 were not taking lipid-lowering medication when enrolled: 392 were normolipidemic controls; 713 had elevated levels of low-density lipoprotein cholesterol; 623 had combined hyperlipidemia; and 290 had hypertriglyceridemia.
RESULTS: Relative to controls, prebeta-1 HDL levels were increased in all 3 dyslipidemic phenotypes, particularly the combined and hypertriglyceridemia groups. This increase possibly reflects increased acceptor capacity of apolipoprotein B-100 containing lipoproteins for entropically driven transfer of cholesteryl esters from HDL via cholesteryl ester transfer protein. Multiple regression analysis revealed that the main predictor variables significantly associated with prebeta-1 HDL levels were apolipoprotein A-I (apoA-1) (β = 0.500), triglyceride (β = 0.285), HDL-C (β = -0.237), and age (β = -0.169). There was an interaction between apoA-1 and sex (female vs male; β = -0.110). Among postmenopausal women, estrogenized subjects had a similar level of prebeta-1 HDL compared to those not receiving estrogens.
CONCLUSIONS: Prebeta-1 HDL levels are elevated in the 3 most common types of hyperlipidemia and are most strongly influenced by the levels of apoA-1, triglyceride, and HDL-C.
Copyright © 2017 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dyslipidemia; HDL; LDL; Lipoproteins; Prebeta-1 HDL; Reverse cholesterol transport; Triglycerides

Mesh:

Substances:

Year:  2017        PMID: 29198898     DOI: 10.1016/j.jacl.2017.11.001

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  4 in total

1.  Genetic and secondary causes of severe HDL deficiency and cardiovascular disease.

Authors:  Andrew S Geller; Eliana Y Polisecki; Margaret R Diffenderfer; Bela F Asztalos; Sotirios K Karathanasis; Robert A Hegele; Ernst J Schaefer
Journal:  J Lipid Res       Date:  2018-10-17       Impact factor: 5.922

Review 2.  The Difference Between High Density Lipoprotein Subfractions and Subspecies: an Evolving Model in Cardiovascular Disease and Diabetes.

Authors:  W Sean Davidson; Allison L Cooke; Debi K Swertfeger; Amy S Shah
Journal:  Curr Atheroscler Rep       Date:  2021-03-27       Impact factor: 5.113

3.  Whole-exome sequencing reveals damaging gene variants associated with hypoalphalipoproteinemia.

Authors:  Weilai Dong; Karen H Y Wong; Youbin Liu; Michal Levy-Sakin; Wei-Chien Hung; Mo Li; Boyang Li; Sheng Chih Jin; Jungmin Choi; Francesc Lopez-Giraldez; Dedeepya Vaka; Annie Poon; Catherine Chu; Richard Lao; Melek Balamir; Irina Movsesyan; Mary J Malloy; Hongyu Zhao; Pui-Yan Kwok; John P Kane; Richard P Lifton; Clive R Pullinger
Journal:  J Lipid Res       Date:  2022-04-20       Impact factor: 6.676

4.  Reduced Reverse Cholesterol Transport Efficacy in Healthy Men with Undesirable Postprandial Triglyceride Response.

Authors:  Alexandre Motte Motte; Julie Gall Gall; Joe-Elie Salem; Eric Dasque; Martine Lebot; Eric Frisdal; Sophie Galier; Elise F Villard; Elodie Bouaziz-Amar; Jean-Marc Lacorte; Beny Charbit; Wilfried Le Goff; Philippe Lesnik; Maryse Guerin
Journal:  Biomolecules       Date:  2020-05-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.